Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Daratumumab in Japanese patients with relapsed/refractory multiple myeloma
NCT02116569Phase 1Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Apr 2014
- Primary completion
- Sep 2015
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of daratumumab in multiple myeloma (MM) (2 arms), sponsored by Janssen Pharmaceutical. Primary endpoints: Dose Limiting Toxicities and Adverse Events. Started Apr 2014; status: completed.
02
Drugs
daratumumab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT02116569.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02116569.